Release abilities of adenosine diphosphate from phospholipid vesicles with different membrane properties and their hemostatic effects as a platelet substitute.
We have constructed phospholipid vesicles with hemostatic activity as a platelet substitute. The vesicles were conjugated with a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). We have recently exploited these vesicles as a potential drug delivery system by encapsulation of adenosine 5'-diphosphate (ADP) (H12-(ADP)-vesicles). Here we explore the relationship between the ADP release from H12-(ADP)-vesicles with different membrane properties and their hemostatic effects. In total, we prepared five kinds of H12-(ADP)-vesicles with different lamellarities and membrane flexibilities. By radioisotope-labeling, we directly show that H12-(ADP)-vesicles were capable of augmenting platelet aggregation by releasing ADP in an aggregation-dependent manner. The amount of ADP released from the vesicles was dependent on their membrane properties. Specifically, the amount of ADP released increased with decreasing lamellarity and tended to increase with increasing membrane flexibility. Our in vivo results clearly demonstrated that H12-(ADP)-vesicles with the ability to release ADP exert considerable hemostatic action in terms of correcting prolonged bleeding time in a busulphan-induced thrombocytopenic rat model. We propose a recipe to control the hemostatic abilities of H12-(ADP)-vesicles by modulating ADP release based on membrane properties. We believe that this concept will be invaluable to the development of platelet substitutes and other drug carriers.
Okamura
Yosuke
Y
Department of Life Science and Medical Bioscience, Graduate School of Advanced Science and Engineering, Waseda University, TWIns, Tokyo 162-8480, Japan.
Katsuno
Shunsuke
S
Suzuki
Hidenori
H
Maruyama
Hitomi
H
Handa
Makoto
M
Ikeda
Yasuo
Y
Takeoka
Shinji
S
D000244:Adenosine Diphosphate / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D000595:Amino Acid Sequence; D000818:Animals; D001760:Bleeding Time; D001792:Blood Platelets / Q000187:drug effects; D001802:Blood Substitutes / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D008081:Liposomes / Q000737:chemistry* / Q000648:ultrastructure; D008297:Male; D010455:Peptides / Q000737:chemistry; D010743:Phospholipids / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013921:Thrombocytopenia / Q000188:drug therapy
D001802:Blood Substitutes; D008081:Liposomes; D010455:Peptides; D010743:Phospholipids; D000244:Adenosine Diphosphate